Saponin Adjuvant TQL-1055 Antigen Dose Sparing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine regimens require multiple doses and large quantities of antigen to achieve effective inoculation, particularly for pandemic pathogens like SARS-CoV-2, leading to delayed herd immunity and challenges in rapid antigen production and distribution during emergencies.
Innovation Solution
The use of synthetic saponin molecules, such as TQL-1055, as adjuvants in vaccines to induce strong priming responses with reduced antigen doses, enabling dose sparing and combination vaccines for multiple pathogens like SARS-CoV-2 and Influenza.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a priming-boosting vaccine regimen is used, then effective inoculation against the pathogen is achieved, but greater vaccine antigen quantities are required and the onset of effective inoculation is delayed
Solution Approach 1:
The patent introduces saponin adjuvants as intermediary substances that mediate between the vaccine antigen and the immune system. These adjuvants enhance the immunogenicity of the antigen, allowing effective immune response with reduced antigen quantities. The adjuvant acts as a mediator that amplifies the signal to the immune system, reducing the need for large amounts of antigen in priming-boosting regimens.
Solution Approach 2:
The patent changes the chemical and immunological parameters of the vaccine composition by incorporating saponin adjuvants. This parameter change transforms the vaccine from one requiring high antigen doses to one that is highly immunogenic at low doses. The saponin adjuvant modifies the immunological response parameters, enabling effective inoculation with substantially reduced antigen quantities.
2Reliability
If a priming-boosting vaccine regimen is used, then effective inoculation is achieved, but the onset of effective inoculation is delayed
Solution Approach 1:
The saponin adjuvant performs preliminary action by pre-conditioning the immune system to respond more vigorously and rapidly to the antigen. The adjuvant prepares the immune environment in advance, creating a state of heightened immunological readiness that accelerates the onset of effective inoculation while maintaining the reliability of the priming-boosting regimen.
Solution Approach 2:
The incorporation of saponin adjuvants changes the temporal parameters of the immune response. The adjuvant modifies the kinetics of immune activation, reducing the lag time between antigen administration and effective immune response. This parameter change in response time enables faster onset of effective inoculation without compromising the ultimate level of protection.
3Ease of manufacture
If vaccine antigen is difficult or expensive to manufacture, then vaccine development is constrained, but only a portion of the affected population may receive the vaccine when needed
Solution Approach 1:
The patent changes the dosage parameter of the vaccine from high antigen content to low antigen content through the use of saponin adjuvants. This parameter change in dosage requirements directly addresses manufacturing constraints by reducing the total quantity of difficult-to-produce antigen needed per dose and per population, thereby improving accessibility and reducing manufacturing burden.
Data Source
AI summary
The present application relates to new vaccines, improved vaccine priming, and antigen dose sparing in connection with triterpene glycoside saponin-derived adjuvants, salt forms thereof, and pharmaceutical compositions, as well as related methods.